Analysis of the controlled essential hypertension’s pharmacotherapy in general practice
- 作者: Slobodyanyuk A.L.1, Kupaev V.I.1
-
隶属关系:
- Samara State Medical University
- 期: 卷 27, 编号 3 (2023)
- 页面: 13-21
- 栏目: Original studies
- URL: https://journals.eco-vector.com/RFD/article/view/456845
- DOI: https://doi.org/10.17816/RFD456845
- ID: 456845
如何引用文章
详细
BACKGROUND: Arterial hypertension is a common cardiovascular disease that requires constant monitoring by a doctor of drug therapy to achieve the target blood pressure level.
AIM: To analyze pharmacotherapy of essential hypertension in patients, who have achieved a controlled course of the disease.
MATERIALS AND METHODS: In this study 274 patients with controlled course of stage 2 arterial hypertension and no comorbidities were recruited. Blood pressure indicators, anthropometric data, results of laboratory and instrumental studies, the volume of drug therapy for hypertension were analyzed.
RESULTS: We analyzed 543 drug prescriptions for 274 patients with stage II hypertension. In 97 (35.3%) patients only one drug was prescribed, in 112 (40.7%) — two drugs, in 46 (16.7%) — three drugs from various pharmacological groups, among which monodrugs were in the lead: angiotensin-converting-enzyme inhibitors — 31.86%, cardioselective β-blockers — 23%, angiotensin 2 receptor blockers — 9.3%. Combined drugs were present in 18.4% of general doctors’ prescriptions. Fixed forms of combined antihypertensive drugs were taken by only 50 (18.4%) patients. To prevent cardiovascular complications of arterial hypertension, 75 (26%) patients were prescribed statins (atorvastatin or rosuvastatin) and 56 (19.5%) — antiplatelet monotherapy with Cardiomagnyl, Thrombo ACC or clopidogrel.
CONCLUSIONS: To achieve the target blood pressure level and control arterial hypertension in patients with stage II hypertension, general practitioners used all main
全文:
作者简介
Anatolii Slobodyanyuk
Samara State Medical University
Email: a.l.slododjanjuk@samsmu.ru
ORCID iD: 0000-0002-2712-4199
md, cand. sci. (med.), assistant professor
俄罗斯联邦, 89 Chapaevskaya St., Samara, 443099Vitalii Kupaev
Samara State Medical University
编辑信件的主要联系方式.
Email: v.i.kupaev@samsmu.ru
ORCID iD: 0000-0003-2639-0003
md, dr. sci. (med), professor
俄罗斯联邦, 89 Chapaevskaya St., Samara, 443099参考
- Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice Eur Heart J. 2016;37(29):2315–2381. doi: 10.1093/eurheartj/ehw106
- Oparil S, Acelajado MC, Bakris GL, et al. Hypertension. Nat Rev Dis Primers. 2018;4:18014. doi: 10.1038/nrdp.2018.14
- Oschepkova EV. Five-year results of realization of federal target program “Prevention and treatment of arterial hypertension in Russian Federation” (2002-2006). Therapeutic Archives. 2007;79(9):25–30. (In Russ.)
- Evstifeeva SE, Gridnev VI, Oschepkova EV. 4-th School for doctors of AH register. Evaluation of treatment and prevention among patients with arterial hypertension in primary care unit (data from hypertension register). Atmosphere. Cardiologiya. 2007;4:18–20. (In Russ.)
- Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368(14):1279–1290. doi: 10.1056/NEJMoa1200303
- Rossi A, Dikareva A, Bacon SL, Daskalopoulou SS. The impact of physical activity on mortality in patients with high blood pressure: a systematic review. J Hypertens. 2012;30(7):1277–1288. doi: 10.1097/HJH.0b013e3283544669
- Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224–2260. doi: 10.1016/S0140-6736(12)61766-8
- Chazova IE, Zhernakova YuV. Diagnosis and treatment of arterial hypertension. Guidelines. Systemic Hypertension. 2019;16(1):6–31. (In Russ.) doi: 10.26442/2075082X.2019.1.190179
- Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290–300. doi: 10.1016/j.amjmed.2008.09.038
- Kim S, Shin DW, Yun JM, et al. Medication adherence and the risk of cardiovascular mortality and hospitalization among patients with newly prescribed antihypertensive medications. Hypertension. 2016;67(3):506–512. doi: 10.1161/HYPERTENSIONAHA.115.06731
- Trukhan DI, Davydov EL. Angiotensin receptor blockers II in the treatment of arterial hypertension in patients with comorbid pathology: the possibilities of candesartan. Consilium Medicum. 2017;19(10):25–32. (In Russ.) doi: 10.26442/2075-1753_19.10.25-32
- Clinical practice guidelines for chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.) doi: 10.15829/1560-4071-2020-4083
- Clinical practice guidelines for stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076. (In Russ.) doi: 10.15829/1560-4071-2020-4076
- Clinical recommendations. Chronic kidney disease (CKD). Nephrology (Saint Petersburg). 2021;25(5):10–82. (In Russ.)
- ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD Russian Journal of Cardiology. 2020;25(4):101–161. (In Russ.) doi: 10.15829/1560-4071-2020-3839
- Glezer MG. Evaluation of antihypertensive efficacy and patient adherence to treatment with the new formulation perindopril arginine (orally disintegrating tablet) in general clinical practice: OPTIMUM program. Kardiologiia. 2016;56(4):36–41. (In Russ.) doi: 10.18565/cardio.2016.4.36-41
- Kryuchkova ON, Itskova EA, Lutay YuA, et al. Achievement of arterial hypertension control via application of perindopril arginine and amlodipine combination. Russian Journal of Cardiology. 2015;128(12):102–106. (In Russ.) doi: 10.15829/1560-4071-2015-12-102-106
- Nebieridze DV. Topical issues of beta-blockers use in various clinical situations. Medical Council. 2018;(12):12–17. (In Russ.) doi: 10.21518/2079-701X-2018-12-12-17